Innovation through HTA: theme for HTAi 2021 Annual Meeting announced
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
Search results
43 results
-
-
Cancer patients to benefit from new histology independent treatment
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
-
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
-
NICE begins phased restart of non-COVID-19 guidance
NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.
-
Steam treatment recommended for men with an enlarged prostate
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue
-
NICE publishes latest COVID-19 guidance on renal transplantation
NICE has published new rapid COVID-19 guidance for children, young people and adults who need or who have had a kidney transplant, and people who are donating a kidney (live donors).
-
NICE recommends treatment for type of small-cell lung cancer
A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
-
NICE chairman Sharmila Nebhrajani begins her new role
NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.
-
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.
-
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has today (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
-
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
-
New COVID-19 guideline on acute kidney injury
NICE has published a new COVID-19 rapid guideline on acute kidney injury (AKI).
-
NICE publishes latest wave of COVID-19 guidelines
The first is on the care of children and young people who are immunocompromised and the second on antibiotics for pneumonia in adults in hospital.
-
NICE joins international collaboratives to respond to the COVID-19 pandemic
NICE is supporting a growing number of international collaborations to share knowledge and identify treatments in response to the COVID-19 pandemic.
-
NICE publishes two new COVID-19 guidelines
NICE has published 2 new rapid COVID-19 guidelines on the care of patients with suspected and confirmed COVID-19.
-
NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
-
NICE publishes new COVID-19 guidelines on severe asthma, pneumonia, rheumatological disorders and symptom management
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.
-
NICE publishes second set of rapid COVID-19 guidelines
The new guidelines cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.
-
NICE updates rapid COVID-19 guideline on critical care
We have listened to concerns raised by patient groups about the application of our rapid COVID-19 critical care guideline.
-
NICE publishes first rapid COVID-19 guidelines
New guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.
-
NICE to produce rapid COVID-19 guidelines
NICE has today (20 March 2020) announced that it is developing a series of rapid guidelines with NHS England/Improvement on the active management of patients with suspected and confirmed COVID-19, and in patients without COVID-19, in a number of clinical areas.
-
NICE publishes its guideline on the diagnosis and management of abdominal aortic aneurysms
NICE has today (19 March 2020) published its guideline on the diagnosis and management of abdominal aortic aneurysms (AAA).
-
Professor Gillian Leng, CBE, appointed as new NICE Chief Executive
NICE has today (18 March 2020) announced that Professor Gillian Leng, CBE, has been appointed as its new Chief Executive.
-
“I don't want to talk about that right now.”
Hannah Everard from Thurrock Council discusses the importance of future planning
-
NICE publishes its first medtech briefing on artificial intelligence software
NICE publishes a Medtech Innovation Briefing on artificial intelligence for analysing CT brain scans
-
Around 10,000 people could benefit from new migraine drug as NICE says it's cost-effective
NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine.
-
On World Kidney Day we find out what patients think of their kidney care
Fiona Loud from Kidney Care UK explains what PREM stands for and how it has impacted care in the UK
-
Helping patients to be heard: What the new NICE guidance means for people with tinnitus
Vai Maheswaran, Audiologist at Action on Hearing Loss UK
-
Strategic collaboration announced by NICE and Health Technology Wales
Collaboration outlines the strategic planning and delivery of independent and authoritative medical technology guidance
-
NICE recommends new 'chemotherapy-free' treatment for lymphoma
A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.
-
Wireless device recommended for treating people with overactive bladder
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
-
Researchers wanted to study the public's views of health-related quality of life
Applications close on Wednesday 4 March 2020
-
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.
-
Broader types of data to be used in development of NICE guidance
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance
-
NICE publishes updated principles
NICE has today, 30 January 2020, published a simple guide to the way we develop our guidance and standards.
-
Nasal spray medicine for treatment-resistant depression not recommended by NICE
More evidence on the clinical and cost effectiveness of esketamine needed
-
Digital and mobile interventions could support regular health services in helping people stop smoking and reduce their risk of obesity, says NICE
Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.
-
Care matters – Working together to get support right for adult carers
Dame Philippa Russell, Vice-President of Carers UK and Topic Adviser for the NICE guideline on Supporting Adult Carers
-
Make use of community pharmacists' skills, says NICE
Community pharmacy teams have the potential to play a greater role in health promotion and prevention says NICE, in a new draft quality standard.
-
NICE encourages further data collection on 'game changing' histology independent cancer drugs
Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t be recommended for use in the NHS because at its current price, it doesn’t have the potential to be cost-effective.
-
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
-
Implantable cardiac monitors detect atrial fibrillation after stroke of unknown cause recommended for routine NHS adoption
Doctors can check on their patients remotely using Reveal LINQ monitor
-
Shared Learning Awards 2020 now accepting entries
Submit your shared learning entry by 4 March 2020 for a chance to be one of our 20 finalists at this year’s NICE Conference